DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.01

Stock Information for DiaMedica Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors
DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.